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INTRODUCTION
Aspirin has been studied as a means of primary and
secondary prevention of cardiovascular events. In those
with a history of cardiovascular disease (CVD), a meta-
analysis of six trials involving 6300 patients found that
the use of low-dose aspirin (£ 325 mg/day) reduced
all-cause mortality by 18%, the number of strokes by
20%, myocardial infarction by 30% and other vascular
events by 30%.1 The benefits of aspirin in those without
a history of CVD have not been as clear2 with its use in
these individuals remaining controversial.
The role of aspirin as a potential chemopreventive
agent for colorectal and other gastrointestinal cancers
continues to evolve, supported by the results of
epidemiological observations and randomized-con-
trolled studies.3–5
Doctors are often unaware of a patient’s use of aspirin
therapy because of patients perception of the safety of
aspirin as well as its widespread promulgation as an
anticancer agent. Clinically, the use of chronic aspirin
therapy can have serious ramifications. Regardless of
the indication for use, aspirin imparts an inherent and
significant increased risk for adverse gastrointestinal
events. A systematic review of 17 epidemiological
studies found that the overall relative risk of serious
upper gastrointestinal complications with aspirin use
was 2.2 [95% confidence interval (CI): 2.1–2.4] in
cohort and nested case–control studies and 3.1 (95% CI:
2.8–3.3) in non-nested case–control studies.6 The risk
for upper gastrointestinal events was elevated even with
low-dose aspirin or the use of buffered formulations.6 In
those receiving non-steroidal anti-inflammatory drugs
(NSAIDs), the concurrent use of aspirin substantially
increases (one- to twofold) the risk for gastrointestinal
events.7
Several strategies exist to reduce the gastrointestinal
effects of aspirin alone or in combination with another
NSAID. These include eradication of Helicobacter pylori
infection and/or the use of proton-pump inhibitor (PPI)
co-therapy.7–9 In a randomized trial of H. pylori-positive
patients with complicated ulcers receiving aspirin
therapy (‡325 mg/day), Lai et al.7 observed that nearly
15% of patients given H. pylori eradication therapy who
resumed aspirin therapy (dose of 100 mg/daily) experi-
enced recurrent ulcer complications after 1 year. In
contrast, an ulcer recurrence rate of <2% was observed
in those treated for H. pylori and given co-therapy with
a PPI following the re-initiation of aspirin therapy
(Figure 1). The use of a PPI or misoprostol co-therapy
has been found to significantly reduce the risk for
recurrent peptic ulceration in patients receiving
NSAIDs10 as well as those receiving an NSAID plus
low-dose aspirin (Figure 2).8
Workshop Consensus on Clinical Management Issues
Is the role of aspirin for cardiovascular prophylaxis or as
chemoprevention of colorectal cancer justifiable given its
risks for gastrointestinal events? While the literature
supports the benefits of aspirin in those with a history
or CVD, its use as primary prevention must be weighed
against the risk for serious gastrointestinal events.2 In
either case, in those patients in whom cardioprotective
aspirin use is warranted the use of PPI co-therapy
should be considered to reduce the risk for gastric injury
and complications.
The role of aspirin as a chemopreventive strategy for
oesophageal or colorectal cancer is still emerging and its
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use cannot be considered a substitute for screening or
surveillance. In the case of oesophageal cancer,3 an
association was demonstrated between aspirin use and
the incidence of malignancy only. The case for secon-
dary prophylaxis of colorectal cancer is stronger,
especially in those who have undergone curative
surgery and in those with familial adenomatous polyp-
osis coli. Because the evidence for colorectal cancer
prevention comes only from secondary prevention trials,
it is premature to recommend the use of aspirin or any
NSAID as a primary cancer chemopreventive strategy.
Does the addition of aspirin to a COX-2 selective NSAID
reduce the gastrointestinal safety of the NSAID? All
workshop participants felt that the addition of aspirin
to a cyclo-oxygenase (COX)-2 selective NSAID regimen
reduced the safety profile of the anti-inflammatory agent
– 88% of these strongly agreed and 12% agreed with
reservation.
Is there enough evidence to suggest aspirin for the secondary
prevention of colon polyps? This proved to be a difficult
issue for workshop participants to agree upon: 38%
strongly agreed that there is enough evidence to suggest
aspirin for the secondary prevention of colon polyps, 31%
agreed with reservation and 31% felt that there is not
enough evidence to warrant this management strategy.
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Figure 2. Patients remaining ulcer-free on chronic non-steroidal
anti-inflammatory drug (NSAID) plus daily low-dose aspirin. A
subanalysis of aspirin taking patients receiving NSAIDs revealed a
lower risk for ulcer recurrence with lansoprazole 15 mg, lansop-
razole 30 mg or misoprostol 200 mcg/day compared with
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*P = 0.008
Figure 1. Placebo-controlled trial of lansoprazole for prevention of
recurrent ulcer complications on low-dose aspirin. Patients who
experienced an ulcer following at least 1 month of aspirin therapy
were treated for Helicobacter pylori, resumed aspirin therapy at a
dose of 100 mg/daily, were significantly less likely to experience
recurrent ulcer complications with lansoprazole co-therapy com-
pared with placebo. Adapted from Lai et al.7
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